Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses AβPP and LRP-1 overexpression in the aged SAMP8 mouse brain

Journal of Alzheimer's Disease

Volumn 28, Issue 4, 2012, Pages 951-960

  Erickson, Michelle A ^a,b   Niehoff, Michael L ^b,c   Farr, Susan A ^b,c   Morley, John E ^b,c   Dillman, Lucy A ^a   Lynch, Kristin M ^a   Banks, William A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Abcb1; amyloid peptides; amyloid protein precursor; antisense; blood brain barrier; LRP1; oligonucleotides; Pgp; RAGE; SAMP8

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; GLYCOPROTEIN P; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE ACCELERATED MOUSE;

EID: 84858020530     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111517     Document Type: Article

References (65)

1. Hossain S, Akaike T, Chowdhury EH (2010) Current approaches for drug delivery to central nervous system. Curr Drug Deliv 7, 389-397.
2. Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C, Janigro D, Leybaert L, Molnar Z, O'Donnell ME, Povlishock JT, Saunders NR, Sharp F, Stanimirovic D, Watts RJ, Drewes LR (2011) Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 12, 169-182.
3. Ueno M, Nakagawa T, Wu B, Onodera M, Huang CL, Kusaka T, Araki N, Sakamoto H (2010) Transporters in the brain endothelial barrier. Curr Med Chem 17, 1125-1138.
4. Zalachoras I, Evers MM, van Roon-Mom WM, Aartsma-Rus AM, Meijer OC (2011) Antisense-mediated RNA targeting: Versatile and expedient genetic manipulation in the brain. Front Mol Neurosci 4, 10.
5. Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-DeMotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA (2009) Testing the neurovascular hypothesis of Alzheimer's disease: LRP- 1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis 17, 553-570.
6. Kumar VB, Farr SA, Flood JF, Kamlesh V, Franko M, Banks WA, Morley JE (2000) Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides 21, 1769-1775. (Pubitemid 32058851)
7. Banks WA, Kumar VB, Morley JE (2004) Influence of ethanol dependence and methionine enkephalin antisense on serum endomorphin-1 and methionine enkephalin levels. Alcohol Clin Exp Res 28, 792-796. (Pubitemid 38661378)
8. Banks WA, Farr SA, Butt W, Kumar VB, Franko MW, Morley JE (2001) Delivery across the blood-brain barrier of antisense directed against amyloid beta: Reversal of learning and mem ory deficits in mice overexpressing amyloid precursor protein. J Pharmacol Exp Ther 297, 1113-1121. (Pubitemid 32472511)
9. Banks WA, Jaeger LB, Urayama A, Kumar VB, Hileman SM, Gaskin FS, Llanza NV, Farr SA, Morley JE (2006) Preproenkephalin targeted antisenses cross the blood-brain barrier to reduce brain methionine enkephalin levels and increase voluntary ethanol drinking. Peptides 27, 784-796.
10. Takeda T, Hosokawa M, Higuchi K (1997) Senescence-accelerated mouse (SAM): A novel murine model of senescence. Exp Gerontol 32, 105-109. (Pubitemid 27131709)
11. Nomura Y, Yamanaka Y, Kitamura Y, Arima T, Ohnuki T, Oomura Y, Sasaki K, Nagashima K, Ihara Y (1996) Senescence-accelerated mouse. Neurochemical studies on aging. Ann N Y Acad Sci 786, 410-418.
12. Morley JE, Kumar VB, Bernardo AE, Farr SA, Uezu K, Tumosa N, Flood JF (2000) Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides 21, 1761-1767. (Pubitemid 32058850)
13. Takemura M, Nakamura S, Akiguchi I, Ueno M, Oka N, Ishikawa S, Shimada A, Kimura J, Takeda T (1993) Beta/A4 proteinlike immunoreactive granular structures in the brain of senescence-accelerated mouse. Am J Pathol 142, 1887-1897. (Pubitemid 24057083)
14. Flood JF, Morley JE (1998) Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev 22, 1-20.
15. Pallas M, Camins A, Smith MA, Perry G, Lee HG, Casadesus G (2008) From aging to Alzheimer's disease: Unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis 15, 615-624.
16. Banks WA, Robinson SM, Verma S, Morley JE (2003) Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: Impairment in a mouse model of Alzheimer's disease. Neuroscience 121, 487-492. (Pubitemid 37176936)
17. Deane R, Zlokovic BV (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4, 191-197. (Pubitemid 46562394)
18. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8, 16-30.
19. Vogelgesang S, Jedlitschky G, Brenn A, Walker LC (2011) The role of the ABC transporter p-glycoprotein in the transport of beta-amyloid across the blood-brain barrier. Curr Pharm Des 17, 2778-2786.
20. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499. (Pubitemid 32038587)
21. Deane R, Wu Z, Zlokovic BV (2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-2631. (Pubitemid 39458354)
22. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH (2000) Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106, 1159-1166.
23. Owen JB, Sultana R, Aluise CD, Erickson MA, Price TO, Bu G, Banks WA, Butterfield DA (2010) Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: Implications for Abeta accumulation in AD brain. Free Radic Biol Med 49, 1798-1803.
24. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112, 405-415. (Pubitemid 44469161)
25. Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH (2002) The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J 21, 5691-5700. (Pubitemid 35315269)
26. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913. (Pubitemid 36889934)
27. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691. (Pubitemid 26282167)
28. Zlokovic BV (2008) New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 5, 409-414.
29. Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31, 246-254.
30. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115, 3285-3290. (Pubitemid 41567593)
31. Hartz AM, Miller DS, Bauer B (2010) Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 77, 715-723.
32. Candela P, Gosselet F, Saint-Pol J, Sevin E, Boucau MC, Boulanger E, Cecchelli R, Fenart L (2010) Apical-to- basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 22, 849-859.
33. Wijesuriya HC, Bullock JY, Faull RL, Hladky SB, Barrand MA (2010) ABC efflux transporters in brain vasculature of Alzheimer's subjects. Brain Res 1358, 228-238.
34. Banks WA, Kumar VB, Farr SA, Nakaoke R, Robinson SM, Morley JE (2011) Impairments in brain-to-blood transport of amyloid-beta and reabsorption of cerebrospinal fluid in an animal model of Alzheimer's disease are reversed by antisense directed against amyloid-beta protein precursor. J Alzheimers Dis 23, 599-605.
35. Hammond RS, Tull LE, Stackman RW (2004) On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem 82, 26-34. (Pubitemid 38737427)
36. Harrison FE, Hosseini AH, McDonald MP (2009) Endogenous anxiety and stress responses in water maze and Barnes maze spatial memory tasks. Behav Brain Res 198, 247-251.
37. Holscher C (1999) Stress impairs performance in spatial water maze learning tasks. Behav Brain Res 100, 225-235.
38. Caterini F, Della Sala S, Spinnler H, Stangalino C, Tumbull OH (2002) Object recognition and object orientation in Alzheimer's disease. Neuropsychology 16, 146-155. (Pubitemid 34284779)
39. Dennett HW, McKone E, Tavashmi R, Hall A, Pidcock M, Edwards M, Duchaine B (2011) The Cambridge Car Memory Test: A task matched in format to the Cambridge Face Memory Test, with norms, reliability, sex differences, dissociations from face memory, and expertise effects. Behav Res Methods. doi: 10.3758/s13428-011-0160-2.
40. Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y (2008) Distinct pools of beta-amyloid in Alzheimer disease-affected brain: A clinicopathologic study. Arch Neurol 65, 906-912. (Pubitemid 352008473)
41. Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ (2008) The use of total protein stains as loading controls: An alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J Neurosci Methods 172, 250-254.
42. Silverberg GD, Miller MC, Messier AA, Majmudar S, Machan JT, Donahue JE, Stopa EG, Johanson CE (2010) Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J Neuropathol Exp Neurol 69, 98-108.
43. Banks WA, Farr SA, Butt W, Kumar VB, Franko MW, Morley JE (2001) Delivery across the blood-brain barrier of antisense directed against amyloid beta: Reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J Pharmacol Exp Ther 297, 1113-1121. (Pubitemid 32472511)
44. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357.
45. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344. (Pubitemid 39061126)
46. Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283, 29639-29643.
47. Klein WL, Krafft GA, Finch CE (2001) Targeting small Abeta oligomers: The solution to an Alzheimer's disease conundrum? Trends Neurosci 24, 219-224. (Pubitemid 32204378)
48. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
49. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H (2011) Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 89, 1031-1042.
50. Klein WL, Stine WB Jr, Teplow DB (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25, 569-580. (Pubitemid 38686476)
51. Yang M, Teplow DB (2008) Amyloid beta-protein monomer folding: Free-energy surfaces reveal alloform-specific differences. J Mol Biol 384, 450-464.
52. Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea JE, Ruotolo BT, Robinson CV, Bowers MT (2009) Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem 1, 326-331.
53. Wu B, Ueno M, Onodera M, Kusaka T, Huang CL, Hosomi N, Kanenishi K, Sakamoto H (2009) Age-related changes in P-glycoprotein expression in senescence-accelerated mouse. Curr Aging Sci 2, 187-192.
54. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK (1995) LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 82, 331-340.
55. Kinoshita A, Whelan CM, Smith CJ, Mikhailenko I, Rebeck GW, Strickland DK, Hyman BT (2001) Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: Role of the intracellular adapter protein Fe65. J Neurosci 21, 8354-8361. (Pubitemid 33051433)
56. Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH (2004) FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 24, 4259-4265. (Pubitemid 38620802)
57. Waldron E, Heilig C, Schweitzer A, Nadella N, Jaeger S, Martin AM, Weggen S, Brix K, Pietrzik CU (2008) LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiol Dis 31, 188-197.
58. Yoon IS, Pietrzik CU, Kang DE, Koo EH (2005) Sequences from the low density lipoprotein receptor-related protein (LRP) cytoplasmic domain enhance amyloid beta protein production via the beta-secretase pathway without altering amyloid precursor protein/LRP nuclear signaling. J Biol Chem 280, 20140-20147. (Pubitemid 41379545)
59. Fuentealba RA, Liu Q, Zhang J, Kanekiyo T, Hu X, Lee JM, LaDu MJ, Bu G (2010) Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS One 5, e11884.
60. Sultana R, Banks WA, Butterfield DA (2010) Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease. J Neurosci Res 88, 469-477.
61. Gouras GK, Tsai J, Naslund J,Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156, 15-20. (Pubitemid 30644433)
62. Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, Serrano J, Bentura ML, Martinez-Murillo R, Martinez A, Rodrigo J (2004) Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. Histol Histopathol 19, 823-844. (Pubitemid 38855065)
63. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK (2008) LDL receptor-related protein 1: Unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 88, 887-918.
64. Miller MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L, Silverberg GD, Stopa EG (2008) Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 1230, 273-280.
65. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56, 66-78. (Pubitemid 47484175)